Circassia Share Discussion Threads

[saadia110] 18/5/2022 21:14

£220,000 buy trades X 2 today. Someone is keen on this.

[p1nkfish] 12/5/2022 09:16

Asthma only increasing imho as even more of the world urbanises and more enter into the net of being able to be diagnosed or exposed to more possible triggers. I do think the way we live aggravates the problem.

[drdre] 12/5/2022 09:03

Can't believe I got a thumbs down for that question :D I understand that there is a vast market of 340m and reading around I really like the company. I just usually see a TAM included in presentations and couldn't find one. Definitely on my to buy list.

[nw99] 12/5/2022 08:42

Great company

[drdre] 12/5/2022 08:33

I have been watching CIR a while and impressed by recent newsflow. Whats the target addressable market they are in?

[p1nkfish] 12/5/2022 07:35

Good reading.

[masurenguy] 12/5/2022 07:18

Excellent trading update, with increased sales, improved gross margins and a projected EBITDA ahead of management expectations, plus a 7% increase in net cash !

Trading Update

We are pleased to report that, despite recent economic events, our business continues to perform well, with clinical revenues for the first four months of the year ahead of management's expectations and up approximately 17% compared with the same period in 2021. Research revenues are also slightly ahead of the previous year. We are conscious that our business in China (14% of sales in 2021) may be affected by the local lockdowns that have occurred since the end of March, but it has traded strongly in the first four months delivering growth in excess of 23% on the same period in 2021.

Since the beginning of the year we have continued to increase our reach into the US national primary care sector, and we now have four major national distributors and sales organisations appointed to date, with further additions planned. Gross margins across the business have been strong and operating expenditure is continuing to decline as a result of the annualisation effect of the restructuring carried out last year and the transition to a distributor-led sales strategy.

As a result of the strong performance in the year to date, the board believes that Group EBITDA for the full year is likely to be materially ahead of its expectations. The unaudited cash balance at 30 April 2022 was GBP13.5m (31 December 2021: GBP12.6m).

Ian Johnson, Circassia's Executive Chairman, said: "I am pleased to be able to report strong trading performance in the year to date, with revenues and Group EBITDA ahead of expectations. The Company continues to benefit from a high degree of recurring revenues and is trading profitably and generating cash. Asthma is one of the biggest healthcare issues globally with 340 million patients, many of whom have uncontrolled symptoms. There is a clear need for a device for patients to use at home to manage their condition better. Circassia is currently addressing this huge unmet clinical need by providing NIOX devices for use by healthcare professionals and is, as a priority, also seeking to address the home-use market with a simplified device. I look forward to updating shareholders again on our further progress and plans at the time of the half-year results."

[pro_s2009] 11/5/2022 07:49

Possibly a cross trade, so signalling the end of the sell order thats been ongoing as someone wants out ?

[dgwinterbottom] 11/5/2022 07:48

An interesting buy of 3.2m shares went through at lunchtime yesterday, wonder if there is any significance in that?

[p1nkfish] 22/3/2022 17:12

Well I'm pleased with these results even if the market isn't today.
A good read and turnaround.

[thedudie] 22/3/2022 08:53

Key bit for me - Revenues up 24% for the first 2 months of the year (compared with last year).

Going well for 2022

[nw99] 22/3/2022 08:02

Nice results

[saadia110] 22/3/2022 07:23

Amazing results today, let's see the price action today.

[masurenguy] 22/3/2022 07:15

Really excellent set of results !

PRELIMINARY RESULTS FOR THE YEARED 31 DECEMBER 2021

Oxford, UK - 22 March 2022: Circassia Group plc, a medical device company focused on point of care asthma diagnosis and management, today announces its audited results for the year ended 31 December 2021.

Financial highlights

-- Revenues were up 17% to £27.9m (20% on a constant currency basis), approximately 84% being recurring consumable revenues

-- Group adjusted EBITDA positive for the first time at £0.6m, ahead of upgraded consensus estimates

-- Profit for the financial year £3.6m after a deferred tax credit of £4.4m (2020: loss of £33.5m)

-- Net cash £12.6m (31 December 2020: £7.4m)

Operational highlights

-- Solid recovery in revenues despite continuing Covid-19 disruption

-- Ongoing transition to distributor-led business model with new arrangements in the USA and China expected to drive scalable revenue growth

-- Transition period for COPD business complete

-- Global Health & Pharma Awards named Circassia as Global Leaders in FeNO testing in 2021

-- Updated American Thoracic Society guidelines recommend FeNO testing for diagnosis and ongoing management of asthma

Ian Johnson, Circassia's Executive Chairman, said: "The Group passed some significant milestones in 2021, achieving positive adjusted EBITDA and a profit after tax for the first time, as well as generating positive cash flow from our operating activities. The Group is debt free and has the cash resources to continue implementing its business strategy of accessing a large and underserved population of patients suffering from asthma.

We anticipate the global pandemic will continue to have some impact on our markets, however, the much-reduced cost base, high levels of recurring revenues and high gross margins will continue to provide a considerable degree of resilience going forward. The business has made a positive start to 2022 with NIOX(R) clinical revenues up 24% in the first two months of the year on the equivalent period in 2021 and has continued to generate positive operating cash flow. The Board believes that the ongoing transition to a distributor led business model will drive top line growth and deliver further shareholder value over the medium term."

[saadia110] 18/3/2022 16:04

More buys today, looking good for next week.

[saadia110] 17/3/2022 19:55

1 million shares bought at 40p at the close today. Good buying today, bodes well for next week.

[saadia110] 10/3/2022 16:27

Volume has picked up in last few days, more people buying in before results are released. If the results are half decent, we could see a significant re-rate.

[thedudie] 10/3/2022 14:38

Price being driven back up today - Recent trading statement said results are on 22 March.

[masurenguy] 10/2/2022 16:28

Took an opening position in CIR earlier today.

[thelongandtheshortandthetall] 28/1/2022 14:39

Probably Ayl30.

Which is good :)

[ayl30] 28/1/2022 14:37

So now we know who was buying, will they keep doing so I wonder?

[ayl30] 28/1/2022 14:25

Now we know who the buyer was. Will they keep buying I wonder?

[sphere25] 27/1/2022 09:59

More large exchanges here. Someone has been in the market for a short while buying in size here but is it enough to clear sellers and allow the breakout?

Worth watching.

All imo
DYOR

[thedudie] 26/1/2022 16:50

Looks like it wants to easily break the recent (last 3 year) highs.
Could be another good day tomorrow!

[thelongandtheshortandthetall] 26/1/2022 16:39

Yeah. So that 's probably about 5% of the company changed hands. I'll bet it's one seller and one buyer.
Holding RNS soon probs.